NCT03372018

Brief Summary

Evidence-based programs to prevent diabetes among high-risk individuals are less effective among those who also have mental health needs. This study involves developing and pilot testing the first adaptation of the landmark Diabetes Prevention Program lifestyle intervention to simultaneously treat prediabetes and elevated mental health symptoms. This project has large potential to impact public health, given that more than half of the U.S. adult population has either of these conditions, and is at risk for developing comorbid diabetes and mental illness.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 13, 2017

Completed
8 months until next milestone

Study Start

First participant enrolled

August 7, 2018

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 22, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 22, 2019

Completed
Last Updated

June 5, 2019

Status Verified

June 1, 2019

Enrollment Period

8 months

First QC Date

December 4, 2017

Last Update Submit

June 3, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Body Weight

    Weight change from baseline.

    3 months

Secondary Outcomes (4)

  • Perceived Stress

    3 months

  • Cardiometabolic marker - A1C

    3 months

  • Cardiometabolic marker - waist circumference

    3 months

  • Beck Depression Inventory

    3 months

Study Arms (2)

Promotora-led intervention (PLI)

EXPERIMENTAL

PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.

Behavioral: Promotora-led Intervention (PLI)

Usual care (UC)

ACTIVE COMPARATOR

UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.

Behavioral: Usual care (UC)

Interventions

Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.

Promotora-led intervention (PLI)
Usual care (UC)BEHAVIORAL

Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.

Usual care (UC)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Latino ethnicity
  • Spanish fluency
  • Age ≥18 years
  • BMI ≥25 kg/m2
  • And "increased risk of diabetes" (ADA Diabetes Risk Score ≥5 as determined by 7-item questionnaire and/or hemoglobin A1C ≥ 5.7%)

You may not qualify if:

  • Hemoglobin A1C ≥ 6.5%
  • Current or planned pregnancy during the study period
  • Chronic conditions that could affect potential participants' ability to participate (osteoarthritis, heart disease, pulmonary disease requiring oxygen or daily bronchodilator use, and severe psychiatric disease)
  • Medical comorbidities that could influence weight loss or weight gain (thyroid disease, cancer, and HIV)
  • Medications that could affect weight or glucose metabolism (thiazide diuretics, β-blockers, and systemic glucocorticoids).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern Univeristy

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Prediabetic StateObesityMetabolic DiseasesBody Weight ChangesDiabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Matthew J O'Brien, MD, MSc

    Assistant Professor of Medicine and Preventive Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Medicine and Preventive Medicine

Study Record Dates

First Submitted

December 4, 2017

First Posted

December 13, 2017

Study Start

August 7, 2018

Primary Completion

March 22, 2019

Study Completion

March 22, 2019

Last Updated

June 5, 2019

Record last verified: 2019-06

Data Sharing

IPD Sharing
Will not share

Locations